Endowed Research Unit for Virological Medicine

[Social Contribution by Viral Vectors]

Institute of Industrial Science, Endowed Chairs

Virological Medicine

Sponsor: GCAT Co., LTD
Period: April 2020 to March 2024

Through the development of recombinant vaccines using genetically recombinant viruses, we promote translational research (TR) by researching and exploring therapeutic medicines for intractable and non-preventable infectious diseases.

Previously, we have successfully developed genetic recombinant bivalent vaccines using vectors such as the measles virus and canine distemper virus. The Nipah virus vaccine using the recombinant measles virus was recognized to be a promising vaccine. Practical implementation and application of the world’s first Nipah virus vaccine is expected. We aim to further develop new innovative vaccines and drug development strategies for severe incurable and unpreventable diseases.

Through collaboration with researchers at The University of Tokyo as well as other domestic and international organizations, we would like to expand the globalization of the philosophy of The University of Tokyo.

Virological Medicine

Project Professor
Misako YONEDA

Professor
Beomjoon KIM

Basic Research

Vaccine Development

Recombinant Virus

Severe Infectious Diseases
Incurable and Unpreventable Diseases

Drug/Treatment Development

Translational Research

Through the development of recombinant vaccines using genetically recombinant viruses, we will research and explore therapeutic medicines for incurable and unpreventable infectious diseases to advance translational research (TR).